Crisaborole is a non-steroidal topical medication used for the treatment of mild-moderate atopic dermatitis. This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and older.
- Mechanism
- Curator reviewed
Inhibition of PDE4 by crisaborole leads to elevated levels of cyclic adenosine monophosphate (cAMP). Increased intracellular levels of cAMP inhibit the NF-kB pathway and suppress the release of pro-inflammatory mediators such as TNF-alfa and various interleukins that play a causative role in psoriasis and atopic dermatitis. Suppression of downstream effects in different cell types may explain the therapeutic role of crisaborole in immune-mediated skin diseases.
- Primary indication
- Intended for the topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.Curator reviewed · 2 structured indications
- Formula / weight
- C14H10BNO3 · 251.05 g/mol (avg)
- First approval
- Canada, 2018 · United States, 2017
- Code names
- AN-2728
- Brand names
Resolves to
USZAGAREISWJDP-UHFFFAOYSA-NSMILESOB1OCC2=C1C=CC(OC1=CC=C(C=C1)C#N)=C2What you can answer from here — as of September 13, 2026
Which drugs share a target with Crisaborole, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account